Scarica l'app Stockscreener
8.57
5.62%
-0.51
Regenxbio Inc Borsa (RGNX) Ultime notizie
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO Investors of Securities Class Action Deadline on April 14, 2026 - marketscreener.com
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit – Company Announcement - Financial Times
Regenxbio Reinforces Case for Its Duchenne Gene Therapy Amid Accelerated Approval Uncertainty - Citeline News & Insights
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Positive interim data for Regenxbio’s gene therapy in DMD - The Pharmaletter
Stifel cuts Regenxbio stock price target to $42 on gene therapy data - Investing.com Nigeria
Insider Sell Alert: Steve Pakola Sells Shares of Regenxbio Inc (RGNX) - GuruFocus
17:55 ETRGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - Longbridge
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com Nigeria
Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock By Investing.com - Investing.com South Africa
REGENXBIO (RGNX) CMO sells 5,124 shares under 10b5-1 plan - Stock Titan
MDA: Vinay away, AA in play for Regenxbio gene therapy? - BioWorld MedTech
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming DeadlinesRGNX - PR Newswire
REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific ConferenceSlideshow - Seeking Alpha
Stifel reiterates Regenxbio stock rating on Duchenne trial data By Investing.com - Investing.com India
Stifel reiterates Regenxbio stock rating on Duchenne trial data - Investing.com
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
ROSEN, A RANKED AND LEADING FIRM, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Regenxbio Says Its Gene Therapy For Muscle Disorder Showed No Evidence Of Liver Injury In Study - Stocktwits
Regenxbio reports positive interim data for Duchenne gene therapy By Investing.com - Investing.com Nigeria
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals - Benzinga
Regenxbio reports positive interim data for Duchenne gene therapy - Investing.com Australia
REGENXBIO (RGNX) Reports Promising Interim Results for Duchenne Gene Therapy - GuruFocus
Regenxbio reports new positive interim data from phase I/II Affinity Duchenne® trial of RGX-202 - marketscreener.com
RGNX SEC FilingsRegenxbio 10-K, 10-Q, 8-K Forms - Stock Titan
REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 - The Malaysian Reserve
Lab Cells Built Different And Therefore Patentable - marketscreener.com
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 – Company AnnouncementFT.com - Financial Times
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class ActionRGNX - Morningstar
What is HC Wainwright's Estimate for REGENXBIO Q1 Earnings? - MarketBeat
Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN
RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP - pharmiweb.com
[144] REGENXBIO Inc. SEC Filing - Stock Titan
REGENXBIO Inc. (NASDAQ: RGNX) Investor Alert: Lawsuit seeks to recover Losses for Investors - openPR.com
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that REGENXBIO Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class ActionRGNX - PR Newswire
Regenxbio stock: Clear Street reiterates Buy on gene therapy data - Investing.com Nigeria
(RGNX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
RGNX'S "Transformational" Promise Became a $2.40 Loss for Investors: Levi & Korsinsky, LLP - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of REGENXBIO, Inc. Investors - The Malone Telegram
REGENXBIO (NASDAQ:RGNX) Shares Gap UpTime to Buy? - MarketBeat
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements - Investing.com Nigeria
Regenxbio at Leerink Global Healthcare Conference: Strategic Pipeline Advancements By Investing.com - Investing.com Canada
H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com India
H.C. Wainwright cuts Regenxbio stock price target to $30 By Investing.com - Investing.com UK
HC Wainwright Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price - MarketBeat
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire
REGENXBIO commends women leadership driving mission on International Womens Day - Traders Union
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages REGENXBIO, Inc. - GlobeNewswire
REGENXBIO Inc. (NASDAQ:RGNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Why REGENXBIO Inc. stock remains a top recommendation2026 Chart Watch & AI Based Trade Execution Alerts - Naître et grandir
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):